Nereus Pharmaceuticals, Inc. (Nereus)

Oncology Corporate Profile

HQ Location

10480 Wateridge Circle
San Diego, CA 92121

Company Description

Nereus Pharmaceuticals is an innovative drug discovery and development company pursuing untapped sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize novel biologically active compounds, the Company's two oncology drug candidates are in Phase I clinical trials. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
plinabulin / NPI-2358vascular disrupting agentNon Small Cell Lung Cancer (NSCLC)II
NPI-0052proteasome inhibitorMultiple MyelomaI
NPI-0052proteasome inhibitorVarious cancer typesI
plinabulin / NPI-2358vascular disrupting agentVarious cancer typesI

View additional information on product candidates here »


Recent News Headlines

There are no news items to display